# A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses

> **NCT06810934** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kara Chew** · enrollment: 80 (estimated)

## Conditions studied

- COVID-19
- SARS-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** CoTend-BXBB (SARS2-30404)
- **BIOLOGICAL:** CoTend-s3BXBB (SARS2-17032)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06810934
- **Lead sponsor:** Kara Chew
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-21
- **Primary completion:** 2027-12
- **Final completion:** 2029-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06810934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06810934, "A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06810934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*